Noticias y eventos de Haemonetics Corp (HAE)

$102.920

+0.072 (+0.07%)Al cierre

Noticias de HAE

5.008-24PRnewswire

Dr. Martin Madaus Appointed Interim CEO of Azenta

8.508-21NASDAQ.COM

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

9.508-15Yahoo Finance

Haemonetics Q2 Earnings Exceed Expectations

6.508-14Yahoo Finance

John Rogers' Q2 2026 Investment Moves

7.508-13NASDAQ.COM

Biotech Stocks Reach 52-Week Highs Driven by Positive Catalysts

6.508-11Yahoo Finance

David Nierenberg's Q2 2026 Investment Moves Revealed

9.508-10Yahoo Finance

HAE Q2 Performance Exceeds Expectations Driven by Plasma Growth

9.508-07NASDAQ.COM

Haemonetics Corp Reports Q1 Earnings

9.508-06seekingalpha

Haemonetics Q1 FY 2027 Earnings: Revenue Growth and Upgraded Outlook

9.508-06seekingalpha

Haemonetics Q1 Earnings Exceed Expectations with Strong Revenue Growth

Ver más noticias

Eventos de HAE

8/18 12:30

Haemonetics Stock Rises 16.2%

Haemonetics is up 16.2%,…

8/18 10:30

Haemonetics Stock Rises 15.2%

Haemonetics is up 15.2%,…

8/18 09:00

Haemonetics Up 9% to $98.50 on CSL Plasma Supply Agreement

Haemonetics up 9% at $98.50 in pre-market on CSL Plasma supply agreement

8/6 06:30

Raises FY27 Revenue Outlook to Increase 5%-8%

Raises FY27 revenue view to up 5%-8% from up 4%-7%.

8/6 06:30

Haemonetics Q1 Revenue $339.38M, Exceeds Expectations

Reports Q1 revenue $339.38M, consensus $327.89M. Chris Simon, Haemonetics' CEO, stated: "We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long term growth and shareholder value."

Ver más eventos

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.